HOME
WHO IS BDA
BDA DELIVERS
KEY PROJECTS
REFERENCE WORK 
PRINCIPALS & ASSOCIATES
CONTACT US 
Business Development Advisors
Reference Work

Eleos Inc. is a development stage biotechnology company founded in November, 2001. The company is developing therapeutics for cancer according to a unique drug targeting strategy that relies on intrinsic differences between the programming of cancer and normal cells, rather than on the traditional approach of targeting molecules that have been hyperactivated as part of the development of the cancer. This strategy has been extensively validated for "p53", the target of the company's lead therapeutic EL625. Blocking p53 in normal cells has been shown to protect animals from the toxic effects of standard cancer therapeutics (anemia, infection, problems with eating and hair loss), while blocking normal p53 cancers sensitizes many cancers to the killing effects of these therapeutics. EL625 has entered Phase II clinical testing and is expected to be the only dual-purpose agent in oncology able to sensitize cancer to chemotherapy and radiation treatments while protecting patients from the toxic damage these treatments often cause.

How Sourced: Board Member

Our involvement: Intellectual property audit, board governance: set-up audit committee; investor presentations; assisted with financing.